38 citations
,
October 2005 in “Expert opinion on therapeutic patents” Selective androgen receptor modulators (SARMs) are a promising type of drug for various health conditions due to their targeted actions.
May 2026 in “Journal of Medicinal Chemistry” dAR-6–1 is a promising new treatment for hair loss that works better than minoxidil.
Onabotulinum toxin A may help treat trichotillomania and promote hair growth.
A new topical treatment for hair loss is effective and safe with faster results.
1 citations
,
September 2023 in “JCEM case reports” GnRH analogues are effective for diagnosing and treating female androgen excess, offering a non-surgical option.
12 citations
,
April 1995 in “Journal of Medicinal Chemistry” The new compounds moderately block a specific enzyme and strongly counteract a male hormone, suggesting potential for treating certain male-related health conditions.
A new topical treatment for hair loss is effective and safe with faster results.
A new topical treatment for hair loss is effective and safe with faster results.
A new topical treatment for hair loss is effective and safe with faster results.
A new topical treatment for hair loss is effective and safe with faster results.
65 citations
,
November 2019 in “European Journal of Pharmacology” Anti-androgen therapy is crucial for treating cancer and hormone-related diseases, even with low testosterone levels.
A new topical treatment for hair loss is effective and safe with faster results.
A new topical treatment for hair loss is effective and safe with faster results.
A new topical treatment for hair loss is effective and safe with faster results.
February 2024 in “Cancers” New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.
6 citations
,
August 2024 in “Steroids” 2 citations
,
September 2025 in “Frontiers in Endocrinology” SARMs show promise but need more evidence to prove they're better than traditional androgens.
22 citations
,
January 2018 in “European urology focus” New drugs and combination therapies are improving treatment for lower urinary tract symptoms.
1 citations
,
November 2015 in “Cochrane library” 5-alpha-reductase inhibitors help treat urinary symptoms from an enlarged prostate.
2 citations
,
September 1992 in “Steroids” New A-homo-B, 19-dinor steroids showed strong antiandrogenic activity without affecting the enzyme 5α-reductase or androgen receptor binding.
April 2017 in “The Journal of urology/The journal of urology” 5-alpha reductase inhibitors slightly reduce urinary symptoms and may lower surgery and acute retention risks in men.
42 citations
,
May 2003 in “Mini-reviews in Medicinal Chemistry” New steroidal compounds could be effective for treating conditions related to 5α-reductase enzyme activity.
35 citations
,
May 2020 in “Frontiers in Pharmacology” Different drugs for prostate-related urinary symptoms work but have various side effects, and treatment should be tailored to the individual.
3 citations
,
February 2019 in “Molecular genetics and metabolism” The combination of tadalafil and finasteride improves urinary symptoms and erectile function in men with enlarged prostates.
36 citations
,
October 2009 in “Journal of biological chemistry/The Journal of biological chemistry” Two new compounds were found to build bone and muscle without affecting reproductive organs and skin oil glands.
February 2026 in “European journal of medical research” Combining α-blockers with 5α-reductase inhibitors improves symptoms and outcomes for severe benign prostatic hyperplasia.
29 citations
,
July 2009 in “BJU international” Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.
May 2017 in “DOAJ (DOAJ: Directory of Open Access Journals)” Using GnRHa agonists helps diagnose and treat ovarian hyperthecosis when surgery isn't possible.
June 2026 in “Expert Opinion on Pharmacotherapy” New treatments for hair loss focus on targeting specific causes to improve effectiveness and safety.
3 citations
,
January 2023 in “Clinical cancer investigation journal” Some cannabinoid derivatives may be more effective than current drugs at targeting proteins relevant to prostate cancer treatment.